Axplora is repositioning its Italian Farmabios site on high-potency APIs as UDCA production moves to its FDA-approved Vizag facility in India, consolidating supply and scaling for global demand.
Acquisition strengthens US peptide manufacturing capabilities and broadens global expertise in complex peptide APIs
Eli Lilly adds $4.5 billion to its Indiana manufacturing programme, funding a new genetic medicine facility and expanded API capacity at Lebanon, taking its total US investment since 2020 past $50 billion.
Cambrex is advancing its $150 million investment to expand API manufacturing in Iowa and enhance R&D and manufacturing capabilities in Milan, strengthening its services in the US and Europe.
Ice Pharma recently announced a strategic expansion beyond its core API business, positioning the company to compete in higher-value finished dosage, nutraceutical, and specialty excipient markets.
Full-building, 15-year lease for 64,000 square feet enables CDMO CordenPharma Colorado to power next-generation peptide development in Boulder, Colorado.
$60 million investment to expand highly potent API (HPAPI) development and manufacturing at Axplora’s Farmabios site in Gropello Cairoli, Italy.
Investment marks continued progress against AbbVie's $100 billion commitment to US R&D and capital investments, including manufacturing, over the next decade.
Siegfried signed binding agreements to acquire three drug substance sites in the US and Australia.
Curia has completed a $4 million upgrade to its sterile API manufacturing suites in Valladolid, Spain, to enhance product quality, safety, and regulatory compliance.
SK Pharmteco has announced a $6.1 million investment to expand its Rancho Cordova, California, facility with new lab and kilo-scale capabilities for solid-phase peptide synthesis and purification.
Cambrex announced a $120 million investment to expand its API manufacturing capacity at its Charles City, Iowa, facility by 40%.
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Houston, Texas.
Ofichem, a European CDMO specialising in high-quality active pharmaceutical ingredients (APIs) and integrated drug development and manufacturing services, has acquired Meribel Pharma Solutions’ site in Uppsala, Sweden.
CDMO Suanfarma appoints Pere Mañé Godina as its new CEO, marking the beginning of a new chapter for the company, focused on industrial consolidation, sustainable innovation, and global expansion.
IMCD Group, a global distribution partner and formulator of specialty chemicals and ingredients, recently announced the expansion of its Pharmaceuticals Technical Centre in Jakarta, Indonesia. This facility will serve as the hub for pharmaceutical development and innovation across Southeast Asia, Australia, and New Zealand.
Cambrex announced that Snapdragon Chemistry, a Cambrex company, has developed a new liquid-phase peptide synthesis (LPPS) technology utilizing active pharmaceutical ingredient (API) batch reactors and continuous flow.
Olon continues its growth path and increases its total production capacity following the acquisition of Huvepharma Italia and its site in Garessio, Cuneo, in the northwestern part of Italy.
Pfizer has commissioned its expanded, highly automated active pharmaceutical ingredient (API) manufacturing facility at the Tuas Biomedical Park in Singapore.
Siegfried, a global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen, Switzerland, has signed binding agreements with Curia Global for the acquisition of an early-phase CDMO site in Grafton, Wisconsin, US.
UK-headquartered contract development and manufacturing organization (CDMO) Sterling Pharma Solutions has invested $3 million at its US facility in Germantown, WI, to expand the company’s integrated antibody-drug conjugate (ADC) development and manufacturing capabilities.
Eli Lilly plans to invest another $5.3 billion in its US manufacturing site Lebanon, Indiana, increasing the company's total investment in this site $9 billion. The investment will expand Lilly's capacity to manufacture active pharmaceutical ingredients (API) for tirzepatide injections marketed under the Zepbound and Mounjaro brands.
The European Chemical Industry Council (CEFIC), through its subgroup European Fine Chemicals Group (EFCG), joined the Critical Medicines Alliance, an initiative of the European Commission to strengthen the supply of critical medicines in Europe.
EuroAPI today announces that its Italian subsidiary, EuroAPI Italy S.R.L., is suspending the production of all APIs (active pharmaceutical ingredients) in Brindisi.
US biotech company Antheia and Olon, an Italian producer of active pharmaceutical ingredients (APIs), have announced the continuation of their ongoing partnership to utilize Olon’s fermentation infrastructure for the scale-up and commercialization of Antheia’s early products.
Israeli generics manufacturer Teva Pharmaceuticals intends to divest its active pharmaceutical ingredient (API) business, Teva API (TAPI). A standalone business unit of Teva, TAPI supplies APIs to over 1,000 customers worldwide and has approximately 4,300 employees worldwide.
Olon Group is building a state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) suite at its Olon USA site in Concord, Ohio. This expands the company's capabilities for handling HPAPI, with investments totaling around €40 million ($43 million) in recent years.
Active pharmaceutical ingredients manufacturer EuroAPI has started a collaboration with Basel, Switzerland-headquartered SpiroChem, a contract research organization (CRO) which specializes in early chemical process R&D (route scouting).
US API maker Veranova has appointed Lucas Sauer-Jones as the company’s vice president & general manager, New England. He will be responsible for Veranova’s sites in Devens and North Andover.
Danish drugmaker Novo Nordisk plans to invest more than 42 billion Danish kroner (about €5.6 billion) starting in 2023 to expand existing manufacturing facilities at the company’s Kalundborg, Denmark, site to meet future market demands.
Olon, an Italian CDMO and API producer of active pharmaceutical ingredients (APIs), plans to invest €10 million in a multi-year expansion of its production site in Mahad, India.
Noramco, a US producer of active pharmaceutical ingredients (APIs), has completed the acquisition of the Cambrex drug product business unit previously known as Halo Pharmaceuticals. Financial details were not disclosed.
EuroAPI's Board of Directors decided that Karl Rotthier would step down as CEO, effective October 30, 2023. They initiated the search for a new CEO and appointed Viviane Monges, the current Board Chair, as interim CEO until a permanent successor is found, while she continues her role as Board Chair.
Contract development and manufacturing organization (CDMO) AmbioPharm has appointed industry veteran Brian Gregg as CEO. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after seven years with the company.
Indian drugmaker Glenmark Pharma has agreed to sell 75% of the shares in its subsidiary Glenmark Life Sciences (GLS) to detergent manufacturer Nirma for 56.515 million Indian rupees (about €639.000).
